Nurix loses any chance of future development, regulatory, or commercial milestone payments and royalties from SAR448272. Its cash runway is unchanged and other drug programs continue, but those facts do not replace the lost payments.
Those payments could have added value if the drug advanced, and Nurix can no longer receive them. Its cash can fund operations into the second half of 2029, and other clinical-stage programs continue. Those strengths reduce the strain on its broader plans, but do not replace the lost chance of payments.
Sanofi ended the SAR448272 trial and program. The source reports no effect on Sanofi's sales, costs, or other programs, so this alone does not change its business outlook.
Follow Nurix Therapeutics (NRIX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NRIX